Further elucidation of the pathogenetic interplay between IL-1β and eicosanoids may contribute to the development of neuroprotective and anti-inflammatory interventions in stroke patients, potentially involving the use of agents such as the IL-1β antagonist anakinra, COX-2 inhibitors, or leukotriene receptor antagonists. Here, PTGS2 is linked to stroke disorder.